Granted Patent
B2
US 12,486,262 · App. 18/373,518 · Granted Dec 2, 2025
Compounds and uses thereof
Assignee:
FOGHORN THERAPEUTICS INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
Claims (11)
1 . A method of treating neurofibromatosis in a subject in need thereof, the method comprising administering to the subject an effective amount of a compound of Formula (I):
or a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the compound of Formula (I) has the structure:
3 . The method of claim 1 , wherein the compound of Formula (I) has the structure:
4 . The method of claim 1 , wherein the compound of Formula (I) has the structure:
5 . The method of claim 1 , wherein the neurofibromatosis is a disorder related to a BRG1 loss of function mutation.
6 . The method of claim 1 , wherein the subject is determined to have a BRG1 loss of function disorder.
7 . The method of claim 1 , wherein the effective amount of the compound reduces the level and/or activity of BRG1 by at least 5% as compared to a reference.
8 . The method of claim 7 , wherein the effective amount of the compound reduces the level and/or activity of BRG1 by at least 5% as compared to a reference for at least 12 hours.
9 . The method of claim 1 , wherein the effective amount of the compound reduces the level and/or activity of BRM by at least 5% as compared to a reference.
10 . The method of claim 9 , wherein the effective amount of the compound reduces the level and/or activity of BRM by at least 5% as compared to a reference for at least 12 hours.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 11, 2023
From: VASWANI, RISHI G.; HUANG, DAVID S.
To: FOGHORN THERAPEUTICS INC.
Reel/Frame 065828/0268 →
Continuity (4)
Provisional Application
62967359
· Jan 29, 2020
References Cited (400)
US 2788341A
· Schwyzer et al.
· 1957
[cited by applicant]
US 3717642A
· Von Strandtmann
· 1973
[cited by applicant]
US 4109496A
· Allemann et al.
· 1978
[cited by applicant]
US 4650796A
· George et al.
· 1987
[cited by applicant]
US 4868103A
· Stavrianopoulos et al.
· 1989
[cited by applicant]
US 5223409A
· Ladner et al.
· 1993
[cited by applicant]
US 5225422A
· Nagata et al.
· 1993
[cited by applicant]
US 5283317A
· Saifer et al.
· 1994
[cited by applicant]
US 5631169A
· Lakowicz et al.
· 1997
[cited by applicant]
US 5677158A
· Zhou et al.
· 1997
[cited by applicant]
US 5801030A
· McVey et al.
· 1998
[cited by applicant]
US 5858358A
· June et al.
· 1999
[cited by applicant]
US 5883223A
· Gray
· 1999
[cited by applicant]
US 6180612B1
· Hockensmith et al.
· 2001
[cited by applicant]
US 6309634B1
· Bankiewicz et al.
· 2001
[cited by applicant]
US 6352694B1
· June et al.
· 2002
[cited by applicant]
US 6551786B2
· Manfredi
· 2003
[cited by applicant]
US 6683058B1
· Tuszynski
· 2004
[cited by applicant]
US 6692964B1
· June et al.
· 2004
[cited by applicant]
US 6716662B2
· Akai
· 2004
[cited by applicant]
US 6797514B2
· Berenson et al.
· 2004
[cited by applicant]
US 6867041B2
· Berenson et al.
· 2005
[cited by applicant]
US 6887466B2
· June et al.
· 2005
[cited by applicant]
US 6905680B2
· June et al.
· 2005
[cited by applicant]
US 6905681B1
· June et al.
· 2005
[cited by applicant]
US 6905874B2
· Berenson et al.
· 2005
[cited by applicant]
US 6995011B2
· Itoh et al.
· 2006
[cited by applicant]
US 7067318B2
· June et al.
· 2006
[cited by applicant]
US 7144575B2
· June et al.
· 2006
[cited by applicant]
US 7172869B2
· June et al.
· 2007
[cited by applicant]
US 7175843B2
· June et al.
· 2007
[cited by applicant]
US 7205103B2
· Emerson
· 2007
[cited by applicant]
US 7232566B2
· June et al.
· 2007
[cited by applicant]
US 7348326B2
· DeSimone et al.
· 2008
[cited by applicant]
US 7572631B2
· Berenson et al.
· 2009
[cited by applicant]
US 8324367B2
· Kaemmerer et al.
· 2012
[cited by applicant]
US 8642660B2
· Goldfarb
· 2014
[cited by applicant]
US 8697359B1
· Zhang
· 2014
[cited by applicant]
US 8703761B2
· Forster et al.
· 2014
[cited by applicant]
US 8771945B1
· Zhang
· 2014
[cited by applicant]
US 8795965B2
· Zhang
· 2014
[cited by applicant]
US 8865406B2
· Zhang et al.
· 2014
[cited by applicant]
US 8945861B2
· Bomgarden et al.
· 2015
[cited by applicant]
US 8946268B2
· Lau et al.
· 2015
[cited by applicant]
US 9072052B2
· Griffin et al.
· 2015
[cited by applicant]
US 9126985B2
· Kley et al.
· 2015
[cited by applicant]
US 9353051B2
· Byrd et al.
· 2016
[cited by applicant]
US 9403843B2
· Thatcher et al.
· 2016
[cited by applicant]
US 9410943B2
· Kadoch et al.
· 2016
[cited by applicant]
US 9546206B2
· Ring et al.
· 2017
[cited by applicant]
US 9546296B2
· Wang et al.
· 2017
[cited by applicant]
US 9636323B2
· Lin et al.
· 2017
[cited by applicant]
US 9656959B2
· Ni et al.
· 2017
[cited by applicant]
US 9694084B2
· Bradner et al.
· 2017
[cited by applicant]
US 9708338B2
· Yukimasa et al.
· 2017
[cited by applicant]
US 9708348B2
· Castro et al.
· 2017
[cited by applicant]
US 9850543B2
· Jagani et al.
· 2017
[cited by applicant]
US 9919998B2
· Ebright et al.
· 2018
[cited by applicant]
US 9932340B2
· Dai et al.
· 2018
[cited by applicant]
US 20020022018A1
· Curiel et al.
· 2002
[cited by applicant]
US 20020037281A1
· Davidson et al.
· 2002
[cited by applicant]
US 20020106632A1
· Manfredi
· 2002
[cited by applicant]
US 20030027335A1
· Ruley et al.
· 2003
[cited by applicant]
US 20040216178A1
· Jones et al.
· 2004
[cited by applicant]
US 20050079512A1
· Emerson et al.
· 2005
[cited by applicant]
US 20050130919A1
· Xu et al.
· 2005
[cited by applicant]
US 20060058255A1
· Chen et al.
· 2006
[cited by applicant]
US 20070105181A1
· Pope et al.
· 2007
[cited by applicant]
US 20080221157A1
· Chakravarty et al.
· 2008
[cited by applicant]
US 20100048565A1
· Frenkel et al.
· 2010
[cited by applicant]
US 20100197621A1
· Henry et al.
· 2010
[cited by applicant]
US 20110003809A1
· Ahrendt
· 2011
[cited by applicant]
US 20120035244A1
· Chinnaiyan et al.
· 2012
[cited by applicant]
US 20140287931A1
· Bernards et al.
· 2014
[cited by applicant]
US 20150057169A1
· Siu et al.
· 2015
[cited by applicant]
US 20160130663A1
· Kohno et al.
· 2016
[cited by applicant]
US 20180140722A1
· Willis et al.
· 2018
[cited by applicant]
US 20180258491A1
· Jagani et al.
· 2018
[cited by applicant]
US 20200069669A1
· Grassian et al.
· 2020
[cited by applicant]
US 20200206344A1
· Kadoch et al.
· 2020
[cited by applicant]
US 20200261434A1
· Choe et al.
· 2020
[cited by applicant]
US 20210171958A1
· Chan et al.
· 2021
[cited by applicant]
US 20210251988A1
· Zhou et al.
· 2021
[cited by applicant]
US 20210260171A1
· Zhou et al.
· 2021
[cited by applicant]
US 20210388040A1
· Kadoch et al.
· 2021
[cited by applicant]
US 20220016083A1
· Centore et al.
· 2022
[cited by applicant]
US 20220396604A1
· Kadoch et al.
· 2022
[cited by applicant]
US 20230079819A1
· Vaswani et al.
· 2023
[cited by applicant]
US 20230129003A1
· Vaswani et al.
· 2023
[cited by applicant]
US 20230149414A1
· Anthony et al.
· 2023
[cited by applicant]
US 20240189318A1
· Huang
· 2024
[cited by applicant]
CN 103038231A
· 2013
[cited by applicant]
CN 105473141A
· 2016
[cited by applicant]
CN 104530013B
· 2016
[cited by applicant]
CN 107531668A
· 2018
[cited by applicant]
EA 202192101A1
· 2021
[cited by applicant]
JP 2000095767A
· 2000
[cited by applicant]
JP 2008505963A
· 2008
[cited by applicant]
JP 2011507910A
· 2011
[cited by applicant]
JP 2011528016A
· 2011
[cited by applicant]
JP 2016520515A
· 2016
[cited by applicant]
WO WO9410300A1
· 1994
[cited by applicant]
WO WO9530761A2
· 1995
[cited by applicant]
WO WO2000024392A1
· 2000
[cited by applicant]
WO WO0059888A1
· 2000
[cited by applicant]
WO WO0059905A1
· 2000
[cited by applicant]
WO WO2005039643A2
· 2005
[cited by applicant]
WO WO2005112620A2
· 2005
[cited by applicant]
WO WO2006005941A1
· 2006
[cited by applicant]
WO WO2006051063A1
· 2006
[cited by applicant]
WO WO2006070806A1
· 2006
[cited by applicant]
WO WO2008022396A1
· 2008
[cited by applicant]
WO WO2008157500A1
· 2008
[cited by applicant]
WO WO2009086303A2
· 2009
[cited by applicant]
WO WO2009111277A1
· 2009
[cited by applicant]
WO WO2010007046A2
· 2010
[cited by applicant]
WO WO2011115998A2
· 2011
[cited by applicant]
WO WO2011132175A2
· 2011
[cited by applicant]
WO WO2012085650A1
· 2012
[cited by applicant]
WO WO2013116663A1
· 2013
[cited by applicant]
WO WO2013116682A1
· 2013
[cited by applicant]
WO WO2014150395A1
· 2014
[cited by applicant]
WO WO2015005473A1
· 2015
[cited by applicant]
WO WO2015002230A1
· 2015
[cited by applicant]
WO WO2015103317A1
· 2015
[cited by applicant]
WO WO2015120320A1
· 2015
[cited by applicant]
WO WO2015121688A1
· 2015
[cited by applicant]
WO WO2016054491A1
· 2016
[cited by applicant]
WO WO2016138114A1
· 2016
[cited by applicant]
WO WO2016160718A1
· 2016
[cited by applicant]
WO WO2016207212A1
· 2016
[cited by applicant]
WO WO2017024318A1
· 2017
[cited by applicant]
WO WO2017060470A1
· 2017
[cited by applicant]
WO WO2017087885A1
· 2017
[cited by applicant]
WO WO2017118734A1
· 2017
[cited by applicant]
WO WO2017158381A1
· 2017
[cited by applicant]
WO WO2018148443A1
· 2018
[cited by applicant]
WO WO2018160636A1
· 2018
[cited by applicant]
WO WO2018175324A1
· 2018
[cited by applicant]
WO WO2019038215A1
· 2019
[cited by applicant]
WO WO2019040098A1
· 2019
[cited by applicant]
WO WO2019138017A1
· 2019
[cited by applicant]
WO WO2019142192A1
· 2019
[cited by applicant]
WO WO2019152437A1
· 2019
[cited by applicant]
WO WO2019152440A1
· 2019
[cited by applicant]
WO WO2019226915A1
· 2019
[cited by applicant]
WO WO2020035779A1
· 2020
[cited by applicant]
WO WO2020081556A2
· 2020
[cited by applicant]
WO WO2020081588A1
· 2020
[cited by applicant]
WO WO2020106915A1
· 2020
[cited by applicant]
WO WO2020127685A1
· 2020
[cited by applicant]
WO WO2020160100A1
· 2020
[cited by applicant]
WO WO2020160180A1
· 2020
[cited by applicant]
WO WO2021081032A1
· 2021
[cited by applicant]
WO WO2021155262A1
· 2021
[cited by applicant]
WO WO2021155264A1
· 2021
[cited by applicant]
WO WO2021155316A1
· 2021
[cited by applicant]
WO WO2021155320A1
· 2021
[cited by applicant]
WO WO2021155321A2
· 2021
[cited by applicant]
WO WO2021183218A1
· 2021
[cited by applicant]
WO WO2021236080A1
· 2021
[cited by applicant]
WO WO2022192621A1
· 2022
[cited by applicant]
WO WO2022198043A1
· 2022
[cited by applicant]
WO WO2023009834A2
· 2023
[cited by applicant]
WO WO2023196560A1
· 2023
[cited by applicant]
WO WO2023196565A1
· 2023
[cited by applicant]
WO WO2023196567A2
· 2023
[cited by applicant]
WO WO2024031875A1
· 2024
[cited by applicant]
WO WO2024086577A1
· 2024
[cited by applicant]
WO WO2024216136A1
· 2024
[cited by applicant]
WO WO2024216151A1
· 2024
[cited by applicant]
WO WO2024249769A2
· 2024
[cited by applicant]
WO WO2025080767A1
· 2025
[cited by applicant]
WO WO2025080769A1
· 2025
[cited by applicant]
No new references.
[cited by examiner]
U.S. Appl. No. 18/281,022, Vaswani et al.
[cited by applicant]
U.S. Appl. No. 18/282,279, Huang, Liyue.
[cited by applicant]
Adamo et al., “The oncogene ERG: a key factor in prostate cancer,” Oncogene 35(4):403-14 (Jan. 28, 2016).
[cited by applicant]
Advani et al., “A Phase 1 study of imatinib mesylate in combination with cytarabine and daunorubicin for c-kit positive relapsed acute myeloid leukemia,” Leuk Res. 34(12):1622-6 (Dec. 2010).
[cited by applicant]
Alazawi, “Foghorn Therapeutics,” Blackseed Bio, last updated Mar. 4, 2022, retrieved Jul. 24, 2023, from <https://blackseedbio.com/reports/fhtx#pipeline> (26 pages).
[cited by applicant]
Anders et al., “HTSeq—a Python framework to work with high-throughput sequencing data,” Bioinformatics 31(2):166-9 (Jan. 15, 2015).
[cited by applicant]
Asangani et al., “Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer,” available in PMC Dec. 12, 2014. Published in final edited form as: Nature. 510(7504):278-82 (2014) (44 pages).
[cited by applicant]
Attard et al., “Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer,” available in PMC Feb. 24, 2009. Published in final edited form as: Oncogene. 27(3):253-63 (2008) (19 pages).
[cited by applicant]
Basuyaux et al., “The Ets transcription factors interact with each other and with the c-Fos/c-Jun complex via distinct protein domains in a DNA-dependent and -independent manner,” J Biol Chem. 272(42):26188-95 (1997).
[cited by applicant]
Bendall et al., “Prevention of amino acid conversion in SILAC experiments with embryonic stem cells,” Mol Cell Proteomics. 7(9):1587-97 (2008).
[cited by applicant]
Berger et al., “Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells,” Cancer Res. 64(24):8867-75 (2004).
[cited by applicant]
Borno et al., “Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation,” Cancer Discov. 2(11):1024-35 (2012).
[cited by applicant]
Camuzeaux et al., “Imaging Erg and Jun transcription factor interaction in living cells using fluorescence resonance energy transfer analyses,” Biochem Biophys Res Commun. 332(4):1107-14 (2005).
[cited by applicant]
Cancer Genome Atlas Research Network, “The Molecular Taxonomy of Primary Prostate Cancer,” Cell. 163(4):1011-25 (2015) (16 pages).
[cited by applicant]
Carell et al., “A novel procedure for the synthesis of libraries containing small organic molecules,” Angew Chem Int Ed Engl. 33(20):2059-2061 (1994).
[cited by applicant]
Carell et al., “A Solution-Phase Screening Procedure for the Isolation of Active Compounds from a Library of Molecules,” Angewandte Chemie International Edition in English. 33(20):2061-2064 (1994).
[cited by applicant]
Chen et al., “ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss,” available in PMC Feb. 1, 2014. Published in final edited form as: Nat Med. 19(8):1023-9 (201…
[cited by applicant]
Chng et al., “A transcriptional repressor co-regulatory network governing androgen response in prostate cancers,” EMBO J. 31(12):2810-23 (2012).
[cited by applicant]
Cho et al., “An unnatural biopolymer,” Science. 261(5126):1303-1305 (1993).
[cited by applicant]
Cull et al., “Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor,” Proc Natl Acad Sci. 89(5):1865-1869. (1992).
[cited by applicant]
Cwirla et al., “Peptides on phage: A vast library of peptides for identifying ligands,” Proc Nati Acad Sci. 87:6378-6382 (1990).
[cited by applicant]
Database Registry, RN 1004932-80-2, entered Feb. 21, 2008 (1 page).
[cited by applicant]
Database Registry, RN 1175782-23-6, entered Aug. 26, 2009 (1 page).
[cited by applicant]
Database Registry, RN 1315743-98-6, entered Aug. 11, 2011 (1 page).
[cited by applicant]
Database Registry, RN 878254-76-3, entered Mar. 28, 2006 (1 page).
[cited by applicant]
Delattre et al., “Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours,” Nature. 359(6391):162-5 (1992).
[cited by applicant]
Demichelis et al., “TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort,” Oncogene 26:4596-4599 (2007).
[cited by applicant]
Devlin et al., “Random Peptide Libraries: a Source of Specific Protein Binding Molecules,” Science. 249(4967):404-406 (1990).
[cited by applicant]
DeWitt et al., “‘Diversomers’: an approach to nonpeptide, nonoligomeric chemical diversity,” Proc Natl Acad Sci. 90(15):6909-6913 (1993).
[cited by applicant]
Dobin et al., “STAR: ultrafast universal RNA-seq aligner,” Bioinformatics. 29(1):15-21 (2013).
[cited by applicant]
Dominguez et al. “Beyond editing: Repurposing CRISPR-Cas9 for Precision Genome Regulation and Interrogation,” available in PMC Jun. 27, 2016, published in final edited form as: Nat Rev Mol Cell Biol. 17(1):5-15 (Jan. 20…
[cited by applicant]
Donaldson et al., “Solution structure of the ETS domain from murine Ets-1: a winged helix-turn-helix DNA binding motif,” EMBO J. 15(1):125-34 (1996).
[cited by applicant]
Erb et al., “Recursive deconvolution of combinatorial chemical libraries,” Proc Natl Acad Sci. 91(24):11422-11426 (1994).
[cited by applicant]
Extended European Search Report for European Application No. 19748410.8, dated Sep. 24, 2021 (10 pages).
[cited by applicant]
Extended European Search Report for European Application No. 19887386.1, dated Dec. 5, 2022 (18 pages).
[cited by applicant]
Extended European Search Report for European Application No. 20749261.2, dated Oct. 18, 2022 (8 pages).
[cited by applicant]
Fathi et al., “Differentiation syndrome with lower-intensity treatments for acute myeloid leukemia,” Am J Hematol. 96(6):735-46 (Jun. 1, 2021) (13 Pages).
[cited by applicant]
Felici et al., “Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector,” J Mol Biol. 222(2):301-10 (1991).
[cited by applicant]
Feng et al., “GFOLD: a generalized fold change for ranking differentially expressed genes from RNA-seq data,” Bioinformatics. 28(21):2782-8 (2012).
[cited by applicant]
Fodor et al., “Multiplexed biochemical assays with biological chips,” Nature. 364:555-556 (1993).
[cited by applicant]
Gaj et al. “ZFN, TALEN and CRISPR/Cas-based Methods for Genome Engineering,” available in PMC Jul. 1, 2014, published in final edited form as: Trends Biotechnol. 31(7):397-405 (Jul. 2013) (20 pages).
[cited by applicant]
Gallop et al., “Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries,” J Med Chem 37(9):1233-51 (1994).
[cited by applicant]
Gene Ontology Consortium, “Gene Ontology Consortium: going forward,” Nucleic Acids Res. 43(Database issue):D1049-56 (2015).
[cited by applicant]
Godwin et al., “Gemtuzumab ozogamicin in acute myeloid leukemia,” Leukemia 31(9):1855-68 (Sep. 2017).
[cited by applicant]
Helgeson et al., “Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer,” Cancer Res. 68(1):73-80 (2008).
[cited by applicant]
Ho et al., “An embryonic stem cell chromatin remodeling complex, esBAF, is essential for embryonic stem cell self-renewal and pluripotency,” Proc Natl Acad Sci U S A. 106(13):5181-6 (2009).
[cited by applicant]
Houghten et al., “The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides,” Biotechniques. 13(3):412-21 (1992).
[cited by applicant]
Ichikawa et al., “An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid leukemia with t(16;21) chromosomal translocation,” Cancer Res. 54(11):2865-8 (1994).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2016/062911 issued May 22, 2018 (13 pages).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2019/015722, issued Aug. 4, 2020 (6 pages).
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2020/033829, issued Nov. 17, 2022 (6 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US19/15722, mailed May 31, 2019 (12 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2016/062911 dated Mar. 3, 2017 (16 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/015605, mailed Jun. 16, 2020 (15 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/015723, mailed Jul. 2, 2020 (15 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2020/033829, mailed Aug. 17, 2020 (14 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2022/019506, dated Jun. 7, 2022 (9 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2023/017839, mailed Sep. 6, 2023 (11 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US21/15876, mailed on Apr. 7, 2021 (23 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US21/15878, dated Jun. 4, 2021 (10 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US23/17821, mailed Jun. 30, 2023 (9 pages).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US23/17829, mailed Aug. 23, 2023 (15 pages).
[cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2019/062525, mailed Feb. 18, 2020 (14 pages).
[cited by applicant]
International Search Report and Written Opinion for PCT/US2022/020943, dated Jun. 14, 2022 (17 pages).
[cited by applicant]
Kadoch et al. “Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma,” available in PMC May 16, 2013, published in final edited form as: Cell. 153(1):71-85 (Mar. 2013) (2…
[cited by applicant]
Kadoch et al., “Mammalian SWI/SNF chromatin remodeling complexes and cancer: Mechanistic insights gained from human genomics,” Sci Adv. 1(5):e1500447 (2015) (17 pages).
[cited by applicant]
Kadoch et al., “Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy,” Nat Genet. 45(6):592-601 (2013) (11 pages).
[cited by applicant]
Kadoch et al., “Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma,” available in PMC May 16, 2013, published in final edited form as: Cell. 153(1):71-85 (2013) (26 pa…
[cited by applicant]
Karim et al., “The ETS-domain: a new DNA-binding motif that recognizes a purine-rich core DNA sequence,” Genes Dev. 4(9):1451-3 (1990).
[cited by applicant]
Klezovitch et al., “A causal role for ERG in neoplastic transformation of prostate epithelium,” Proc Natl Acad Sci U S A. 105(6):2105-10 (2008).
[cited by applicant]
Kumar-Sinha et al., “Recurrent gene fusions in prostate cancer,” available in PMC Jul. 16, 2009. Published in final edited form as: Nat Rev Cancer. 8(7):497-511 (2008) (29 pages).
[cited by applicant]
Kunderfranco et al., “ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer,” PLoS One. 5(5):e10547 (2010) (17 pages).
[cited by applicant]
Lam et al., “A new type of synthetic peptide library for identifying ligand-binding activity,” Nature. 354(6348):82-84 (1991).
[cited by applicant]
Lam, “Application of combinatorial library methods in cancer research and drug discovery,” Anticancer Drug Des. 12(3):145-67 (1997).
[cited by applicant]
Langmead et al., “Fast gapped-read alignment with Bowtie 2,” available in PMC Apr. 1, 2013. Published in final edited form as: Nat Methods. 9(4):357-9 (2012) (8 pages).
[cited by applicant]
Link et al., “Targeting the BAF57 SWI/SNF subunit in prostate cancer: a novel platform to control androgen receptor activity,” Cancer Res. 68(12):4551-8 (2008).
[cited by applicant]
Love et al., “Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2,” Genome Biol. 15(12):550 (2014) (21 pages).
[cited by applicant]
Lupien et al., “FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription,” Cell. 132(6):958-70 (2008).
[cited by applicant]
Machanick et al., “MEME-ChIP: motif analysis of large DNA datasets,” Bioinformatics. 27(12):1696-7 (2011).
[cited by applicant]
Mackereth et al., “Diversity in structure and function of the Ets family PNT domains,” J Mol Biol. 342(4):1249-64 (2004).
[cited by applicant]
Madura et al., “N-recognin/Ubc2 interactions in the N-end rule pathway,” J Biol Chem. 268(16):12046-54 (1993).
[cited by applicant]
McBride et al., “Disruption of mammalian SWI/SNF and polycomb complexes in human sarcomas: mechanisms and therapeutic opportunities,” J Pathol. 244(5): 638-649 (Apr. 2018).
[cited by applicant]
Melé et al., “The human transcriptome across tissues and individuals,” available in PMC Aug. 24, 2015. Published in final edited form as: Science. 348(6235):660-5 (2015) (12 pages).
[cited by applicant]
Mounir et al., “ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor,” Elife. 5:e13964 (2016) (19 pages).
[cited by applicant]
Nagaich et al., “Rapid periodic binding and displacement of the glucocorticoid receptor during chromatin remodeling,” Mol Cell. 14(2):163-74 (2004).
[cited by applicant]
Nam et al., “Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer,” Br J Cancer. 97(12):1690-5 (2007).
[cited by applicant]
Office Action for Chinese Patent Application No. 201980023925.9, dated Apr. 20, 2022 (13 pages).
[cited by applicant]
Ong et al., “A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC),” Nat Protoc. 1(6):2650-60 (2006).
[cited by applicant]
Papillon et al., “Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers,” J Med Chem. 61(22):10155-72 (Nov. 2018).
[cited by applicant]
Partial Supplementary European Search Report for European Patent Application No. 19887386.1, dated Jul. 20, 2022 (23 pages).
[cited by applicant]
Paulo et al., “FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer,” Genes Chromosomes Cancer. 51(3):240-9 (2012).
[cited by applicant]
Petrovics et al., “Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome,” Oncogene. 24(23):3847-52 (2005).
[cited by applicant]
Pomerantz et al., “The androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis,” available in PMC May 1, 2016. Published in final edited form as: Nat Genet. 47(11):1346-51 (2015) (17 pages…
[cited by applicant]
Prensner et al., “The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex,” available in PMC May 1, 2014. Published in final edited form as: Nat Genet. 45(11):1392-8 (2013)…
[cited by applicant]
PubChem CID 117640569, “N-[2-[[4-(4-Methoxyphenyl)-1,3-thiazol-2-yl]amino]-2-oxoethyl]-1,3-thiazole-5-carboxamide,” https://pubchem.ncbi.nlm.nih.gov/compound/117640569, created Feb. 23, 2016 (9 pages).
[cited by applicant]
PubChem CID 56442706, “1-(4-Methoxyphenyl)-N-[2-oxo-2-[4-(1,2,4-triazol-1-yl) anilino]ethyl]pyrazole-3-carboxamide,” https://pubchem.ncbi.nlm.nih.gov/compound/56442706, created Jan. 25, 2012 (8 pages).
[cited by applicant]
PubChem CID 91946137, “N-[2-[(1-Ethylpyrazol-3-yl}amino]-2-oxoethyl]-1-methylpyrazole-3-carboxamide,” https://pubchem.ncbi.nlm.nih.gov/compound/91946137, created Oct. 22, 2015 (8 pages).
[cited by applicant]
PubChem Compound Summary for CID 155037309, dated Dec. 19, 2020 (9 pages).
[cited by applicant]
PubChem Compound Summary for CID No. 136572628, “4-Chloro-N-[2-(cyclopentylamino)-2-oxoethyl]-5-nitro-1H-pyrazole-3-carboxamide,” created Jan. 24, 2019, <https://pubchem.ncbi.nlm.nih.gov/compound/136572628>, (7 pages).
[cited by applicant]
PubChem Compound Summary for CID No. 49726797, “N-Methyl-N-(2-oxo-2-((4-(pyridin-3-yl)thiazol-2-yl)amino)ethyl)-1H-indole-3-carboxamide,” created Nov. 27, 2010, <https://pubchem.ncbi.nlm.nih.gov/compound/49726797>, (8 p…
[cited by applicant]
PubChem Compound Summary for CID No. 91945707, “N-[2-[(4,5-Dimethyl-1,3-thiazol-2-yl)amino]-2-oxoethyl]-1-methylpyrazole-3-carboxamide,” created Oct. 22, 2015 <https://pubchem.ncbi.nlm.nih.gov/compound/91945707>, (8 pag…
[cited by applicant]
PubChem Compound Summary for PubChem CID 49726798, “N-(2-((4-(Furan-2-yl)thiazol-2-yl)amino)-2-oxoethyl)-N-methyl-1H-indole-3-carboxamide,” created Nov. 27, 2010 <https://pubchem.ncbi.nih.gov/compound/49726798> (8 pages…
[cited by applicant]
PubChem Compound Summary for SID 172131678, dated Dec. 9, 2014 (8 pages).
[cited by applicant]
PubChem, “Compound Summary for CID 108452511,” <https://pubchem.ncbi.nlm.nih.gov/compound/108452511>, created Jan. 15, 2016, retrieved Jan. 4, 2021 (7 pages).
[cited by applicant]
PubChem, “Compound Summary for CID 2955118,” <https://pubchem.ncbi.nlm.nih.gov/compound/2955118>, created Jul. 29, 2005, retrieved Mar. 22, 2017 (13 pages).
[cited by applicant]
PubChem, “Compound Summary for CID 7325930,” <https://pubchem.ncbi.nlm.nih.gov/compound/7325930>, created Jul. 29, 2006, retrieved Mar. 22, 2017 (11 pages).
[cited by applicant]
PubChem, “Compound Summary for CID 970466,” <https://pubchem.ncbi.nlm.nih.gov/compound/970466>, created Jul. 9, 2005, retrieved Mar. 22, 2017 (11 pages).
[cited by applicant]
Quinlan et al., “BEDTools: a flexible suite of utilities for comparing genomic features,” Bioinformatics. 26(6):841-2 (2010).
[cited by applicant]
Rajput et al., “Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers,” J Clin Pathol. 60(11):1238-43 (2007).
[cited by applicant]
Rappsilber et al., “Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips,” Nat Protoc. 2(8):1896-906 (2007).
[cited by applicant]
Scott et al., “Searching for peptide ligands with an epitope library,” Science. 249(4967):386-390 (1990).
[cited by applicant]
Shen et al., “The SWI/SNF ATPase Brm is a gatekeeper of proliferative control in prostate cancer,” Cancer Res. 68(24):10154-62 (Dec. 2008).
[cited by applicant]
Shi et al., “Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation,” Genes Dev. 27(24):2648-62 (Dec. 2013).
[cited by applicant]
Siegel et al., “Cancer statistics, 2015,” CA Cancer J Clin. 65(1):5-29 (2015).
[cited by applicant]
Subramanian et al., “Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles,” Proc Natl Acad Sci USA. 102(43):15545-50 (2005).
[cited by applicant]
Sun et al., “TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation,” available in PMC Oct. 4, 2020. Published in final edited form as: Oncog…
[cited by applicant]
Tikdari et al., “Reaction of 2-Aminothiazoles with 5-Oxazolones,” ChemInform. 18(47):Abstract 199 (1987) (1 page).
[cited by applicant]
Tikdari et al., “Reaction of 2-Aminothiazoles with 5-Oxazolones,” Indian Journal of Chemistry 26B:478-9 (May 1987).
[cited by applicant]
Tomlins et al., “Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer,” Science.310(5748):644-8 (2005).
[cited by applicant]
Tomlins et al., “Role of the TMPRSS2-ERG gene fusion in prostate cancer,” Neoplasia. 10(2):177-88 (2008) (21 pages).
[cited by applicant]
Tomlins et al., “TMPRSS2: ETV4 gene fusions define a third molecular subtype of prostate cancer,” Cancer Res. 66(7):3396-400 (2006).
[cited by applicant]
Tsai et al. “Dimeric CRISPR RNA-guided Fokl Nucleases for Highly Specific Genome Editing,” available in PMC Dec. 1, 2014, published in final edited form as: Nat Biotechnol. 32(6):569-576 (Jun. 2014) (22 pages).
[cited by applicant]
Tuoc et al., “Chromatin regulation by BAF170 controls cerebral cortical size and thickness,” Dev Cell. 25(3):256-69 (May 2013).
[cited by applicant]
Vachtenheim et al., “SWI/SNF chromatin remodeling complex is critical for the expression of microphthalmia-associated transcription factor in melanoma cells,” Biochemical and Biophysical Research Communications. 392(3):…
[cited by applicant]
Varambally et al., “The polycomb group protein EZH2 is involved in progression of prostate cancer,” Nature. 419(6907):624-9 (2002).
[cited by applicant]
Vela et al., “Discovery of Enhancers of the Secretion of Leukemia Inhibitory Factor for the Treatment of Multiple Sclerosis,” J Biomol Screen. 21(5):437-45 (Jun. 2016).
[cited by applicant]
Verger et al., “Identification of amino acid residues in the ETS transcription factor Erg that mediate Erg-Jun/Fos-DNA ternary complex formation,” J Biol Chem. 276(20):17181-9 (2001).
[cited by applicant]
Wollenick et al., “Synthetic transactivation screening reveals ETV4 as broad coactivator of hypoxia-inducible factor signaling,” Nucleic Acids Res. 40(5):1928-43 (2012).
[cited by applicant]
Yang et al., “EZH2, an epigenetic driver of prostate cancer,” Protein Cell. 4(5):331-41 (2013).
[cited by applicant]
Yildirim et al., “Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells,” Cell. 147(7):1498-510 (2011).
[cited by applicant]
Yu et al., “An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression,” Cancer Cell. 17(5):443-54 (2010).
[cited by applicant]
Yu et al., “Direct recruitment of polycomb repressive complex 1 to chromatin by core binding transcription factors,” Mol Cell. 45(3):330-43 (2012).
[cited by applicant]
Zervos et al., “Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites,” Cell. 72(2):223-32 (1993).
[cited by applicant]
Zhang et al., “Model-based analysis of ChIP-Seq (MACS),” Genome Biol. 9(9):R137 (2008) (9 pages).
[cited by applicant]
Zong et al., “ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells,” Proc Natl Acad Sci U S A. 106(30):12465-70 (Jul. 2009).
[cited by applicant]
Zuckermann et al., “Discovery of Nanomolar Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted)glycine Peptoid Library,” J Med Chem. 37(17):2678-2685 (1994).
[cited by applicant]
Zvarec et al., “5-Benzylidenerhodanine and 5-benzylidene-2-4-thiazolidinedione based antibacterials,” Bioorg Med Chem Lett. 22(8):2720-2 (2012).
[cited by applicant]
U.S. Appl. No. 63/543,464, Wan et al.
[cited by applicant]
U.S. Appl. No. 63/543,467, Piel et al.
[cited by applicant]
U.S. Appl. No. 63/707,938, Adam et al.
[cited by applicant]
“Compound Summary: N-[(S)-1-[[4-[6-[(2R,6S)-2,6-Dimethylmorpholino]-2-pyridyl]-2-thiazolyl]amino]-3-methoxy-1-oxo-2-propyl]-1-(methylsulfonyl)-1H-pyrrole-3-carboxamide,” PubChem. CID: 156818027, <https://pubchem.ncbi.nl…
[cited by applicant]
Caira, Mino R. “Crystalline polymorphism of organic compounds.” Design of Organic Solids (1998): 163-208 (46 pages).
[cited by applicant]
CAS, “FHD-286 Cas registration information,” dated Feb. 19, 2025 (6 pages).
[cited by applicant]
Examination Report for European Patent Application No. 22772286.5, dated Jul. 17, 2025 (5 pages).
[cited by applicant]
Extended European Search Report for European Application No. 22772286.5, dated Dec. 17, 2024 (8 pages).
[cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2024/050665, mailed Jan. 28, 2025 (15 pages).
[cited by applicant]
Kumar et al., “Diazanaphthalen-3-yl carboxamides as inhibitors of proteins of the Wnt pathway and their preparation,” Database Caplus. (Jan. 2019) (12 pages).
[cited by applicant]
Piel et al., International Application No. PCT/US2024/050660, filed Oct. 10, 2024 by applicant Foghorn Therapeutics Inc. (35 pages).
[cited by applicant]
Selleck Chemicals, “Safety Data Sheet: FHD-286,” <https://www.selleckchem.com/msds/MSDS_E1178.pdf>, entry date Jan. 1, 2025 (2 pages).
[cited by applicant]
Wan et al., International Application No. PCT/US2024/050665, filed Oct. 10, 2024 by applicant Foghorn Therapeutics Inc. (112 pages).
[cited by applicant]
“Form S-1 Registration Statement: Foghorn Therapeutics Inc.,” as filed with the United States Securities and Exchange Commission on Oct. 2, 2020 (230 pages).
[cited by applicant]
Collins et al., “Abstract 2122: The dual BRM/BRG1 (SMARCA2/4) inhibitor FHD-286 induces differentiation in preclinical models of AML,” Cancer Res. 83(7_Supplement) (Apr. 2023) (5 pages).
[cited by applicant]
Fiskus et al., “Pre-Clinical Efficacy of Targeting Baf Complexes through Inhibition of the Dual Atpases BRG1 and BRM By FHD-286 in Cellular Models of AML of Diverse Genetic Background,” Blood. 140(Supplement 1):8819-20 …
[cited by applicant]
Hentemann, “Abstract ND14: Pharmacological profile and anti-tumor properties of FHD-286: A novel BAF inhibitor for the treatment of transcription factor-driven cancers,” Cancer Res. 82(12_Supplement): ND14 (Jun. 2022) (…
[cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2024/031875, mailed Oct. 18, 2024 (15 pages).
[cited by applicant]
International Search Report and Written Opinion for PCT/US2024/050660, mailed Nov. 26, 2024 (12 pages).
[cited by applicant]
Selleck Chemicals, “Safety Data Sheet: FHD-286,” <https://www.selleckchem.com/msds/MSDS_E1178.pdf>, revised May 1, 2014 (2 pages).
[cited by applicant]
“FLI1 gene,” MedlinePlus, published May 1, 2012, <https://medlineplus.gov/genetics/> (3 pages).
[cited by applicant]
Adam et al., International Application No. PCT/US2024/024407, filed Apr. 12, 2024 by applicant Foghorn Therapeutics Inc. (42 pages).
[cited by applicant]
Adam et al., International Application No. PCT/US2024/024428, filed Apr. 12, 2024 by applicant Foghorn Therapeutics Inc. (40 pages).
[cited by applicant]
Boulay et al., “Cancer-Specific Retargeting of BAF Complexes by a Prion-like Domain,” Cell 171(1):163-78 (Sep. 21, 2017) (36 pages).
[cited by applicant]
CAS RN: 1223164-86-0; STN entry date: May 14, 2010; N-[2-[[4-(3-Fluoro-4-methoxyphenyl)-2-thiazolyl]amino]-2-oxoethyl]-2-methyl-3-furancarboxamide (1page).
[cited by applicant]
CAS RN: 1300403-14-8; STN entry date May 25, 2011; 5-Methyl-N-[2-oxo-2-[ (5-phenyl-2-pyridinyl)amino]ethyl]-2-thiophenecarboxamide (1 page).
[cited by applicant]
CAS RN: 924410-17-3; STN entry date: Mar. 2, 2007; 5-Methyl-N-[2-oxo-2-[ (4-phenyl-2-thiazolyl)amino]ethyl]-2-thiophenecarboxamide (1 page).
[cited by applicant]
CAS RN: 924420-04-2; STN entry date: Mar. 2, 2007; 5-Methyl-N-[2-oxo-2-[[4-(4-pyridinyl)-2-thiazolyl]amino]ethyl]-2-thiophenecarboxamide (1 page).
[cited by applicant]
Centore et al., “Abstract 1224: Discovery of novel BAF inhibitors for the treatment of transcription factor-driven cancers,” Poster Presentations—Proffered abstracts, Cancer Research 81(13_Supplement):1224 (Jul. 1, 2021…
[cited by applicant]
Chandler et al., “ARID1a-DNA interactions are required for promoter occupancy by SWI/SNF,” Mol Cell Biol. 33(2):265-80 (Jan. 2013).
[cited by applicant]
Chattopadhyay et al., “Uveal melanoma: From diagnosis to treatment and the science in between,” Cancer. 122(15):2299-2312 (26 pages) (Aug. 2016).
[cited by applicant]
Coban et al., “Synthesis, biological activity screening and molecular modeling study of acylaminoacetamide derivatives,” Med Chem Res. 24(10):3710-29 (Jul. 25, 2015).
[cited by applicant]
Danziger et al., Automated site-directed drug design: a general algorithm for knowledge acquisition about hydrogen-bonding regions at protein surfaces, Proc R Soc Lond B Biol Sci. 236(1283): 101-113 (Mar. 1989) (14 page…
[cited by applicant]
Database Registry, RN 1323331-37-8, entered Aug. 25, 2011 (1 page).
[cited by applicant]